Review



follow cdk1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc follow cdk1
    miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of <t>CDK1/cyclin</t> B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.
    Follow Cdk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/follow+cdk1/CDK2+XP+Rabbit+mAb/pmc12311963-48-6-8
    Average 96 stars, based on 152 article reviews
    follow cdk1 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway"

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway

    Journal: Biochemistry and Biophysics Reports

    doi: 10.1016/j.bbrep.2025.102177

    miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of CDK1/cyclin B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.
    Figure Legend Snippet: miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of CDK1/cyclin B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.

    Techniques Used: Binding Assay, Expressing, Transfection, Reverse Transcription Polymerase Chain Reaction, Luciferase, Reporter Assay, Activity Assay, Western Blot

    Related Articles

    Binding Assay:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Expressing:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Transfection:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Luciferase:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Reporter Assay:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Activity Assay:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.

    Western Blot:

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway
    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).. The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.The secondary antibodies are goat anti-mouse IgG-HRP (Invitrogen #31430; dilution = 1:10,000) or goat anti-rabbit IgG-HRP (Invitrogen #31460; dilution = 1:15,000) against the primary antibodies.



    Similar Products

    follow cdk1  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc follow cdk1
    miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of <t>CDK1/cyclin</t> B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.
    Follow Cdk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/follow+cdk1/CDK2+XP+Rabbit+mAb/pmc12311963-48-6-8
    Average 96 stars, based on 1 article reviews
    follow cdk1 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cyclin a s-phase progression via cdk2 and mitosis entry following cdk1 activation  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology cyclin a s-phase progression via cdk2 and mitosis entry following cdk1 activation
    miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of <t>CDK1/cyclin</t> B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.
    Cyclin A S Phase Progression Via Cdk2 And Mitosis Entry Following Cdk1 Activation, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/follow+cdk1/Cdk1+Inhibitor/pm27094702-164-13-18
    Average 90 stars, based on 1 article reviews
    cyclin a s-phase progression via cdk2 and mitosis entry following cdk1 activation - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of CDK1/cyclin B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.

    Journal: Biochemistry and Biophysics Reports

    Article Title: miR-21-5p inhibitor enhances the radiosensitivity of human cervical cancer cells via blocking CPEB3-mediated CDK1/cyclin B pathway

    doi: 10.1016/j.bbrep.2025.102177

    Figure Lengend Snippet: miR-21-5p inhibitor directly targeting CPEB3-mediated suppression of CDK1/cyclin B. (A) Bioinformatics analysis revealed the predicted binding sites between miR-21-5p and CPEB3; (B) Effect of miR-21-5p on mRNA expression level of CPEB3 in human cervical cancer cells. HeLa or SiHa cells were transfected with miR-21-5p for 48 h, the mRNA expression level of CPEB3 was determined by RT-PCR; (C) Luciferase reporter assay was performed to measure the binding activity and key binding sites between CPEB3 and miR-21-5p; (D) Effect of miR-21-5p on the expression of CPEB3-mediated CDK1/cyclin B. HeLa or SiHa cells were treated by miR-21-5p inhibitor for 48 h, the expression of CPEB3, CDK1, Cyclin B and β-actin were determined by immunoblot analysis; ∗∗p < 0.01.

    Article Snippet: The information of primary antibodies as follow CDK1 (CST #18048), cyclin B (CST # #12231), β-actin (CST #3700), CPEB3 (Invitrogen #12669-1-AP).

    Techniques: Binding Assay, Expressing, Transfection, Reverse Transcription Polymerase Chain Reaction, Luciferase, Reporter Assay, Activity Assay, Western Blot